Compare BRSP & HQL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRSP | HQL |
|---|---|---|
| Founded | 2017 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Investment Managers |
| Sector | Real Estate | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 528.9M | 521.2M |
| IPO Year | 2017 | N/A |
| Metric | BRSP | HQL |
|---|---|---|
| Price | $3.70 | $16.79 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $5.97 | N/A |
| AVG Volume (30 Days) | ★ 1.9M | 120.2K |
| Earning Date | 10-27-2026 | 01-01-0001 |
| Dividend Yield | ★ 16.89% | 11.56% |
| EPS Growth | ★ 75.24 | N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | ★ $330,587,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.19 | N/A |
| P/E Ratio | ★ N/A | $21.82 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.70 | $15.66 |
| 52 Week High | $6.17 | $22.67 |
| Indicator | BRSP | HQL |
|---|---|---|
| Relative Strength Index (RSI) | 29.26 | 27.65 |
| Support Level | N/A | $16.16 |
| Resistance Level | $3.94 | $17.47 |
| Average True Range (ATR) | 0.11 | 0.62 |
| MACD | 0.02 | -0.06 |
| Stochastic Oscillator | 10.34 | 2.39 |
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.